Pharming Group N.V.

Board/Management Information • Aug 6, 2012

P H A R M I N G

DIRECTORATE CHANGE

Leiden, The Netherlands, August 3, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announces that Karl Keegan, Chief Financial Officer, is leaving the Company in order to pursue a position based in the UK. Karl will step down from his role as CFO and resign from the Board of Management and the Company as of end of August. In view of the recently announced downsizing of the organization and Karl's upcoming departure, the future size of the Board of Management will also be evaluated. Following Karl's departure, his responsibilities as CFO will be assigned to Sijmen de Vries, Chief Executive Officer.

Sijmen de Vries, Pharming CEO, said: "On behalf of Pharming I would like to thank Karl for his hard work and significant contribution since joining the Company two years ago, particularly his efforts in securing financing for the Company in the face of challenging funding conditions for biotechs. We wish Karl all the best in his future endeavours."

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RUCONEST® is partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is undergoing Phase III clinical development. The product is also being evaluated for follow-on indications in the areas of transplantation and reperfusion injury. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. A feasibility study, using the validated transgenic rabbit platform, aimed at the development of recombinant Factor VIII for the treatment of Haemophilia A is underway with partner, Renova Life, Inc. Additional information is available on the Pharming website, www.pharming.com. To download the Pharming Group Investor Relations App, click here.

Contact

Sijmen de Vries, CEO: T: +31 (0)71 524 7400 Karl Keegan, CFO: T: +31 (0)71 524 7400

FTI Consulting Julia Phillips/ John Dineen, T: +44 (0)207 269 7193

#